Abstract
Antiviral drug therapy can effectively suppress HIV replication, but emerging viral resistance and drug toxicity limit long-term therapeutic efficacy. In addition, regeneration of the T helper cell repertoire is often incomplete. The current major challenges in the treatment of HIV infection are therefore the reconstitution of cellular immunity, and especially of the HIV-specific immune response, and the suppression of virus replication in patients with HAART failure. Several gene therapeutic strategies for immune reconstitution of AIDS patients have been described. Preclinical and clinical studies have examined the safety and efficacy of two basic approaches: firstly, the transfer of autologous T cells armed with recombinant receptors that target HIV antigens to specifically increase antiviral immunity and, secondly, the transfer of genetically modified T cells or hematopoietic progenitor cells that express an antiviral gene. However, for both approaches, engraftment levels of gene-modified cells have not been sufficient to reconstitute cellular immunity and to effectively reduce the overall viral load in patients. Strategies to improve the technologies and procedures involved in gene therapeutic immune reconstitution of AIDS patients are discussed.
Keywords: HIV infection, stem cell transplantation, T cell therapy, immune reconstitution
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Gene Therapeutic Approaches for Immune Modulation in AIDS
Volume: 6 Issue: 2
Author(s): Dorothee von Laer, Christopher Baum, Axel Schambach, Klaus Kuhlcke, Roland Zahn, Sebastian Newrzela, Jan van Lunzen, R. Paul Johnson and Jorn E. Schmitz
Affiliation:
Keywords: HIV infection, stem cell transplantation, T cell therapy, immune reconstitution
Abstract: Antiviral drug therapy can effectively suppress HIV replication, but emerging viral resistance and drug toxicity limit long-term therapeutic efficacy. In addition, regeneration of the T helper cell repertoire is often incomplete. The current major challenges in the treatment of HIV infection are therefore the reconstitution of cellular immunity, and especially of the HIV-specific immune response, and the suppression of virus replication in patients with HAART failure. Several gene therapeutic strategies for immune reconstitution of AIDS patients have been described. Preclinical and clinical studies have examined the safety and efficacy of two basic approaches: firstly, the transfer of autologous T cells armed with recombinant receptors that target HIV antigens to specifically increase antiviral immunity and, secondly, the transfer of genetically modified T cells or hematopoietic progenitor cells that express an antiviral gene. However, for both approaches, engraftment levels of gene-modified cells have not been sufficient to reconstitute cellular immunity and to effectively reduce the overall viral load in patients. Strategies to improve the technologies and procedures involved in gene therapeutic immune reconstitution of AIDS patients are discussed.
Export Options
About this article
Cite this article as:
von Laer Dorothee, Baum Christopher, Schambach Axel, Kuhlcke Klaus, Zahn Roland, Newrzela Sebastian, van Lunzen Jan, Paul Johnson R. and Schmitz E. Jorn, Gene Therapeutic Approaches for Immune Modulation in AIDS, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (2) . https://dx.doi.org/10.2174/187152307780598081
DOI https://dx.doi.org/10.2174/187152307780598081 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vivo Imaging of Apoptosis in Cancer: Potentials and Drawbacks of Molecular Probes
Current Molecular Imaging (Discontinued) Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Insertional Mutagenesis by Retroviral Vectors: Current Concepts and Methods of Analysis
Current Gene Therapy An Overview of Synthesis of Indole Alkaloids and Biological Activities of Secondary Metabolites Isolated from Hyrtios Species
Mini-Reviews in Medicinal Chemistry Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research Meet Our Editorial Board Member
Current Stem Cell Research & Therapy <i>Anastatica hierochuntica </i>Extracts: Promising, Safe and Selective Anticancer Agents
The Natural Products Journal The Aging of the Adaptive Immune System
Current Immunology Reviews (Discontinued) On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy
Current Medicinal Chemistry Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy
Current Medicinal Chemistry Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?
Current HIV Research The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Is there a Possible Single Mediator in Modulating Neuroendocrine–thymus Interaction in Ageing?
Current Aging Science Synthesis and Evaluation of New Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets